<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180713</url>
  </required_header>
  <id_info>
    <org_study_id>WILK10554</org_study_id>
    <nct_id>NCT00180713</nct_id>
  </id_info>
  <brief_title>Simvastatin as a Treatment for Pulmonary Hypertension</brief_title>
  <official_title>Simvastatin as a Treatment for Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and efficacy of adding simvastatin to
      the current conventional treatment regimen for the management of pulmonary hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is a disease that is characterised by progressive
      narrowing of the blood vessels of the lungs. This results in a pressure load on the heart and
      heart failure.

      The narrowing is in part due to constriction but mostly due to structural changes in affected
      vessels. The structural changes affect all cell components of the vessel wall (the
      endothelial lining, the muscle layer and fibrous tissue) and can lead to local clot
      formation. In addition there is evidence of inflammation of the vessels and what is known as
      oxidative stress. The disease may occur with no obvious cause, when it is known as
      idiopathic, but it can also be associated with a variety of other diseases, including
      congenital heart disease, collagen vascular disease and HIV infection.

      Current approaches to the treatment of pulmonary hypertension are unsatisfactory as they do
      not prevent disease progression and do not directly or adequately address many of the
      processes detailed above. Alternative or additional treatments are therefore required and an
      attrative approach is to use a statin (a 3-hydroxy-3-methylglutaryl-coenzymeA, or HMG-CoA,
      reductase inhibitor). Statins are widely used for their ability to lower blood cholesterol
      but increasing evidence indicates that these drugs also have direct effects on cell
      components of the vessel wall - including inhibiting inflammation, clot formation and
      oxidative stress - that might be beneficial in pulmonary hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Right Ventricular Mass From Baseline</measure>
    <time_frame>6 months post study treatment</time_frame>
    <description>As measured by cardiac magnetic resonance (the study is powered to detect an 8.5g difference in RV mass between the two treatments, based on reproducibility measurements of RV mass in healthy volunteers and patients)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute Walk Distance</measure>
    <time_frame>6 months</time_frame>
    <description>Change in distance achieved in 6 minute walk test from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV Mass</measure>
    <time_frame>6 months</time_frame>
    <description>Change in LV mass from baseline based on cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Levels of BNP</measure>
    <time_frame>6 months</time_frame>
    <description>Change in NT-proBNP levels compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Score</measure>
    <time_frame>6 months</time_frame>
    <description>Change in quality of life score from baseline as measured by Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) scored from 1-25, with higher scores indicating worse quality of life, the investigator reported the score change.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm 1: Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
    <arm_group_label>Arm 2: Experimental</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once daily.</description>
    <arm_group_label>Arm 1: Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with idiopathic PAH or PAH related to collagen vascular disease

          -  Age 18 years or over

          -  Receiving conventional therapy with diuretics, digoxin, warfarin, sildenafil and
             bosentan. Stable for 1 month

          -  6 minute walk distance between 150m and 450m

          -  Modified NYHA functional class II or III

        Exclusion Criteria:

          -  PAH from a cause other than permitted by entry criteria

          -  Change in PAH treatment in past 4 weeks

          -  Patients requiring prostanoid therapy

          -  Patients already taking a statin

          -  Clinically significant disturbance of liver function - AST or ALT &gt;3xULM; bilirubin
             &gt;1.5xULM

          -  Contraindication for a magnetic resonance scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Wilkins, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine II, Klinikstrasse 36 D-35392</name>
      <address>
        <city>Gie√üen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital, Sydney Street</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital, Du Cane Road</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, Howard L, Nihoyannopoulos P, Mohiaddin RH, Gibbs JS; Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010 May 15;181(10):1106-13. doi: 10.1164/rccm.2009111-699OC.</citation>
    <PMID>20460548</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>July 11, 2019</results_first_submitted>
  <results_first_submitted_qc>August 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Statins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Control</title>
          <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Experimental</title>
          <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Control</title>
          <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Experimental</title>
          <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" lower_limit="24" upper_limit="73"/>
                    <measurement group_id="B2" value="43.2" lower_limit="19" upper_limit="67"/>
                    <measurement group_id="B3" value="46.2" lower_limit="19" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Right Ventricular Mass From Baseline</title>
        <description>As measured by cardiac magnetic resonance (the study is powered to detect an 8.5g difference in RV mass between the two treatments, based on reproducibility measurements of RV mass in healthy volunteers and patients)</description>
        <time_frame>6 months post study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Control</title>
            <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Experimental</title>
            <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular Mass From Baseline</title>
          <description>As measured by cardiac magnetic resonance (the study is powered to detect an 8.5g difference in RV mass between the two treatments, based on reproducibility measurements of RV mass in healthy volunteers and patients)</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="13.9"/>
                    <measurement group_id="O2" value="-5.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6-minute Walk Distance</title>
        <description>Change in distance achieved in 6 minute walk test from baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Control</title>
            <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Experimental</title>
            <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-minute Walk Distance</title>
          <description>Change in distance achieved in 6 minute walk test from baseline</description>
          <units>metres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="57"/>
                    <measurement group_id="O2" value="3.1" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed by intention to treat at 6 months and per protocol at 12 months. Missing variables were replaced with medians or means (for variables missing at baseline) or with expected variables calculated on the percentage change between baseline and 24 weeks observed for the group (placebo or statin) as a whole (a technique called imputation). Missing variables accounted for less than 5% of the data and there were no missing CMR data at baseline.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LV Mass</title>
        <description>Change in LV mass from baseline based on cardiac MRI</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Control</title>
            <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Experimental</title>
            <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LV Mass</title>
          <description>Change in LV mass from baseline based on cardiac MRI</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="10.9"/>
                    <measurement group_id="O2" value="1.7" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed by intention to treat at 6 months and per protocol at 12 months. Missing variables were replaced with medians or means (for variables missing at baseline) or with expected variables calculated on the percentage change between baseline and 24 weeks observed for the group (placebo or statin) as a whole (a technique called imputation). Missing variables accounted for less than 5% of the data and there were no missing CMR data at baseline.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Levels of BNP</title>
        <description>Change in NT-proBNP levels compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Control</title>
            <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Experimental</title>
            <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Levels of BNP</title>
          <description>Change in NT-proBNP levels compared to baseline</description>
          <units>fmol/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="224"/>
                    <measurement group_id="O2" value="-75" spread="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Score</title>
        <description>Change in quality of life score from baseline as measured by Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) scored from 1-25, with higher scores indicating worse quality of life, the investigator reported the score change.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Control</title>
            <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Experimental</title>
            <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Score</title>
          <description>Change in quality of life score from baseline as measured by Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) scored from 1-25, with higher scores indicating worse quality of life, the investigator reported the score change.</description>
          <units>change of score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="4.7"/>
                    <measurement group_id="O2" value="-1.6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from date of consent until the final study visit after a year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Control</title>
          <description>Placebo tablet once daily
Placebo: Placebo tablet once daily.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Experimental</title>
          <description>Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
Simvastatin: Simvastatin 40mg od for 1 month, then 80mg od for 11 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine Kinase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Standard terms of model non-commercial agreement for UK clinical research apply.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Martin R Wilkins</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 8383 2049</phone>
      <email>m.wilkins@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

